Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 3/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4226993 | 0.83 | KDM1A (0.44) | KDM1AMAOAMAOB | |
| Trifluoroacetic Acid SCHEMBL4380019 | 0.72 | SSTR4 (0.45) | CHRM4CHRM3CHRM5CHRM1SSTR4 | |
| SCHEMBL4226587 | 0.67 | MTNR1A (0.50) | CYP1A2 | |
| SCHEMBL4237168 | 0.66 | MTNR1A (0.34) | — | |
| SCHEMBL4227830 | 0.65 | CACNA2D1 (0.36) | — | |
| SCHEMBL4227423 | 0.65 | KDM4E (0.43) | ALDH1A1 | |
| SCHEMBL11836806 | 0.65 | SLC6A2 (0.53) | SSTR4SSTR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11836822 | 0.65 | SLC6A2 (0.53) | SSTR4SSTR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11836792 | 0.65 | SLC6A2 (0.53) | SSTR4SSTR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4232958 | 0.64 | BCAT2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096104-A1 | Organic diamines as mGluR7 modulators | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080242698-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242698-A1 | Organic Compounds | AOC1, OTC, ODC1 | CHRM4 3158/4885CHRM3 2668/4885CHRM5 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.